Sea Pharmaceuticals Partners with Inotiv to Develop CNS Treatments

Sea Pharmaceuticals has announced a strategic collaboration with Inotiv Inc. to advance its pre-clinical neurotherapeutic molecules targeting CNS disorders. The partnership focuses on the development of Sea's lead molecule, SPM-0404, a potential oral treatment for tinnitus, epilepsy, and sporadic ALS (S-ALS). Both companies aim to leverage Inotiv's expertise in IND-enabling studies to assess SPM-0404 levels in clinical trials.

SPM-0404 and its second-generation molecule, SPM-0606, are designed to modulate the excitatory neurotransmitter glutamate pathway, acting as dual AMPAR/KAINR antagonists. These molecules could provide new therapeutic options for patients with limited current treatments, particularly for conditions like tinnitus, epilepsy, and ALS.

This collaboration signifies a crucial step for Sea in filing an IND application with the FDA, potentially bringing innovative oral treatments to patient populations with significant unmet needs.